|1.||Heshmati, F: 1 article (07/2011)|
|2.||Caillot, D: 1 article (07/2011)|
|3.||Lapierre, V: 1 article (07/2011)|
|4.||Azar, N: 1 article (07/2011)|
|5.||Chabannon, C: 1 article (07/2011)|
|6.||Makowski, C: 1 article (07/2011)|
|7.||Auperin, A: 1 article (07/2011)|
|8.||Moreau, P: 1 article (07/2011)|
|9.||Rossi, J-F: 1 article (07/2011)|
|10.||Vekhof, A: 1 article (07/2011)|
|1.||Non-Hodgkin Lymphoma (Lymphosarcoma)
05/01/1997 - "Recombinant methionyl human stem cell factor and filgrastim for peripheral blood progenitor cell mobilization and transplantation in non-Hodgkin's lymphoma patients--results of a phase I/II trial."
05/01/1997 - "To examine the safety and efficacy of recombinant-methionyl human stem cell factor (r-metHuSCF), 38 patients with intermediate-grade or immunoblastic high-grade non-Hodgkin's lymphoma who were eligible for autologous transplantation were randomized to receive r-metHuSCF (5, 10, 15, or 20 microg/kg/d) plus Filgrastim (10 microg/kg/d) or Filgrastim (10 microg/kg/d) alone to mobilize peripheral blood progenitor cells. "
|2.||Breast Neoplasms (Breast Cancer)
02/01/2003 - "Twenty-three patients with previously treated stage II-IV breast cancer received cyclophosphamide (3 g/m(2)), Filgrastim 5 microg/kg daily and r-metHuSCF 20 microg/kg daily. "
02/01/1995 - "Bone marrow (BM) aspirate and biopsy specimens from seven female patients with advanced or metastatic breast cancer and preserved marrow function treated on a phase I trial of recombinant methionyl human stem cell factor (r-metHuSCF; SCF) were evaluated by immunohistochemical staining before and after treatment with SCF. "
02/01/2003 - "Mobilization of peripheral blood progenitor cells with a combination of cyclophosphamide, r-metHuSCF and filgrastim in patients with breast cancer previously treated with chemotherapy."
01/01/2011 - "Priming with r-metHuSCF and filgrastim or chemotherapy and filgrastim in patients with malignant lymphomas: a randomized phase II pilot study of mobilization and engraftment."
01/01/2011 - "In this study we report results from this combination after a phase II trial of 32 patients with malignant lymphoma randomized to receive recombinant methionyl human SCF (ancestim, r-metHuSCF) in combination with recombinant methionyl human G-CSF (filgrastim, r-metHuG-CSF) (experimental arm A) or routine chemotherapy plus filgrastim (conventional arm B). "
10/01/2004 - "In total, 20 cancer patients unable to provide adequate PBPC products after a previous mobilization attempt were treated with ancestim (20 microg/kg/day s.c.) and filgrastim (10 microg/kg/day s.c.). "
07/01/2011 - "Ancestim (r-metHuSCF) plus filgrastim and/or chemotherapy for mobilization of blood progenitors in 513 poorly mobilizing cancer patients: the French compassionate experience."
|5.||B-Cell Chronic Lymphocytic Leukemia (Chronic Lymphocytic Leukemia)
|3.||Granulocyte Colony-Stimulating Factor (G-CSF)
|5.||Stem Cell Factor
|2.||Drug Therapy (Chemotherapy)
|3.||Transplantation (Transplant Recipients)
|5.||Stem Cell Transplantation